

Note 1 Therapeutic class	Drugs	Licensed for psoriatic arthritis	Patient and clinical considerations Refer to dermatology local guidance for further details
Anti-TNF	Yuflyma® SC (Adalimumab £) Remsima® IV/SC (Infliximab ££ or £) Cimzia® SC (Certolizumab pegol £££) Benepali® SC (Etanercept ££)	Yes (all)	Contraindications: Demyelinating disease, heart failure (etanercept cautioned for both) Yuflyma®/Remsima® first line biologics in Crohn's disease Cimzia® is the drug of choice in pregnant or lactating patients or those who are planning a pregnancy Cimzia® is contraindicated in latex allergy
Anti IL-17	Bimzelx® SC (Bimekizumab ££) Taltz® SC (Ixekizumab £££) Cosentyx® SC (Secukinumab £££) Kyntheum® SC (Brodalumab £££)	Yes Yes No Yes	Avoid in Inflammatory Bowel Disease IL-17 as a class is considered to be relatively fast onset of action compared to other options Cosentyx® is contraindicated in latex allergy Kyntheum® is cautioned in patients with depression
Anti IL-23	Ilumetri® SC (Tildrakizumab ££) Tremfya® SC (Guselkumab ££) Skyrizi® SC (Risankizumab £££)	No Yes Yes	Continuous homecare nursing service available if adherence concerns or if patients are unable to self-inject
Anti IL-12/23	Pyzchiva® SC (Ustekinumab £)	Yes	Continuous homecare nursing service available but may need further discussion regarding funding for this Also used in the management of Inflammatory Bowel Disease
PDE4 inhibitor	Generic apremilast® PO (£)	Yes	Oral therapy and requires less monitoring than other options Cautioned in patients with depression
TYK2 inhibitor	Sotyktu® PO (Deucravacitinib ££)	No	Oral therapy which requires no monitoring Not as effective as other biological options but more effective than apremilast. Cautioned in patients with VTE, malignancy or major adverse cardiovascular events (MACE)